Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Overall survival (OS) · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin leads to higher haematological adverse event: Grade 3/4 anaemia compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in neurological adverse event: Grade 3/4 neuropathy, not otherwise… compared with tri‐weekly paclitaxel plus carboplatin (low certainty).
1 finding from 1 review
Overall Survivalclinical observation · patients with ovarian cancer
Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).
1 finding from 1 review
Progression‐free survival · patients with ovarian cancer
Topotecon+Carboplatin+Paclitaxel may leads to higher progress free survival compared with carboplatin+Paclitaxel (low certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
1 finding from 1 review
Intervention not reported
BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).
1 finding from 1 review